目的回顾性分析4种乳腺癌分子分型的临床特点并对-济宁医学院学报.docVIP

乳腺癌分子分型在新辅助化疗中的疗效预测 史亚飞1路海2李磊3张仁亚3刘启龙1,2 （1济宁医学院附属医院乳腺甲状腺外科，山东济宁272000；2济宁医学院, 山东济宁272067;3济宁医学院附属医院病理科，山东济宁 272000） 摘要 回顾性分析4种乳腺癌分子分型的临床特点，比较其在新辅助化疗方案中的疗效。方法 选取本院初治并接受新辅助化疗的172例乳腺癌患者的病历资料进行回顾性分析，根据免疫组织化学结果，将乳腺癌患者分为4种亚型：LuminalA型、LuminalB型、Her-2过表达型和basal-like型。对不同亚型患者的临床资料进行分析，比较4种亚型乳腺癌患者在新辅助化疗中的疗效。结果 172例乳腺癌患者中，LuminalA型占47.1%，LuminalB型占23.8%，Her-2过表达型占11.6%，Basal-like型占16.3%；四种亚型的病理完全缓解率分别为11.1%、12.2%、35.0%、42.9%。Basal-like型病理完全缓解率明显高于Luminal A亚型和Luminal B亚型（P=0.012）。结论 乳腺癌分子亚型可作为病理完全缓解的独立预测因子，为乳腺癌个体化治疗提供依据。 关键词乳腺癌；分子分型；新辅助化疗；临床特征 The Role of Breast Cancer Subtypes in the Prediction of Neoadjuvant Chemotherapy Yafei Shi, Hai Lu, Lei li, Yaren Zhang, Qilong Liu The Affiliated Hospital Of Jining Medical College, Jining, 272000 Abstract:The clinical?characteristics of 4 breast cancer subtypes were analyzed retrospectively and therapeutic effect of neoadjuvant chemotherapy was compared. Methods 172 cases of patients with breast cancer treated with neoadjuvant chemotherapy were included in this retrospective study. Molecular subtypes were categorized as Luminal A subtype, Luminal B subtype, HER-2 overexpression subtype and basal-like subtype, based on the immunohistochemistry results. The clinical data were analyzed and therapeutic effect of neoadjuvant chemotherapy was compared in 4 different types of breast cancer. Results Among all 172 cases, the proportion of Luminal A subtype was 47.1%; Luminal B subtype was 23.8%; HER-2 overexpression subtype was 11.6%; basal-like subtype was 16.3%, respectively. The pathologic complete remission rate of the four subtypes were: 11.1%、12.2%、35.0%、42.9%. The pathologic complete?remission rate of patients with basal-like subtype was significantly higher than that of patients with Luminal A subtype and Luminal B subtype. (P=0.012). Conclusion Four types of breast cancer subtypes could be the independent indicator of the pathologic complete?remission and the basis for individualized treatment of breast cancer. Subject words: Br